MSD (Merck & Co) is planning to get its RSV vaccine, clesrovimab, approved and launched before the next RSV season in 2025–26, after reporting positive results from a Phase IIb/III trial. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results